[ 89 Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer

ConclusionTumor uptake on [89Zr]Zr-cetuximab PET/CT failed to predict treatment benefit in patients withRAS wild-type mCRC receiving cetuximab monotherapy.BRAF mutations, right-sidedness, and low sEGFR correlated with intrinsic resistance to cetuximab.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research